CD274 and cancer: Among all 530 patients, the incidence of irHepatitis was significantly higher among patients with melanoma than among those with other cancers (6%, 6/98 vs. 0.5%, 2/432, P < 0.001); the incidence of irHepatitis was also higher among patients receiving anti-CTLA-4 inhibitor than among those receiving anti-PD-1/PD-L1 inhibitors (14%, 7/50 vs. 0.2%, 1/480, P < 0.001).